Latest Announcements

Euro Pratik Sales Ltd has scheduled a Board Meeting on 05/11/2026 to consider and approve Audited Standalone and Consolidated Financial Results for the quarter and half year ended on 30th September, 2026.

Piramal Pharma Ltd has announced its unaudited financial results for Q2 and H1 FY27, with revenue growth of 28% YoY and 23% YoY respectively, driven by strong performance across all three businesses. EBITDA increased 72% YoY in Q2FY27 and H1FY27, with over 350bps EBITDA margin expansion in both periods.

Madhav Infra Projects Ltd has announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with a limited review report from its statutory auditors. The company has drawn attention to a non-ascertainment and non-provision of Deferred Tax Liability as per Ind AS 12 Income Taxes.

Star Health and Allied Insurance Company Ltd has declared unaudited standalone financial results for the quarter and half year ended September 30, 2026, and reclassified Sthitaprajna Advisors LLP from Promoter Group Category to Public Shareholder Category.

Advait Energy Transitions Ltd has announced an earnings call for Q2/H1-FY26 results, scheduled on November 2, 2026, at 11:00 a.m. IST.

Zee Entertainment Enterprises Ltd has announced a Board meeting on October 30, 2026, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026. A conference call with investors will also be held on the same day.

Piramal Pharma Ltd has announced its unaudited financial results for Q2 FY 27, with revenue from operations at Rs 1,345.38 crore and net profit after tax at Rs 170.74 crore.

Shree Ganesh Remedies Ltd has scheduled a Board Meeting on October 31, 2026, to consider and approve the Unaudited Financial Results for the quarter and half year ended September 30, 2026.

Madhav Infra Projects Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026, along with a rights issue of up to Rs. 49.00 crores.

Aarti Drugs Ltd has scheduled a Board Meeting on November 3, 2026, to consider and approve Audited Financial Results for the quarter and half year ended September 30, 2026.

Trident Lifeline Ltd has revised its unaudited financial statement for the half year ended 30.09.2026 due to an inadvertent error in the previously filed results.

Capri Global Capital Ltd has announced its unaudited financial results for Q2 and half year ended September 30, 2026, with the Board of Directors approving the same at its meeting held on October 27, 2026.

Onesource Specialty Pharma Ltd has made available the audio recording of its earnings call for the quarter ended September 30, 2026, on its website.

Piramal Pharma Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026, with a net profit of Rs. 170.74 crore and a revenue from operations of Rs. 1,345.38 crore.

Steel Authority of India Ltd has released its Q2 and H1 FY'27 results, showing a 15.43% EBITDA margin and a PAT of Rs. 3410 crore. The company has also provided an economic scenario update, citing improved growth projections for the global and Indian economies.

Trident Lifeline Ltd has resubmitted its financial results for the half year ended 30.09.2026 due to an inadvertent error in the previously filed results. The company has attached the revised financial result and has requested the exchange to consider the revised filing.

Gayatri Projects Ltd has scheduled a Board Meeting on 4th November 2026 to consider and approve the Unaudited Standalone and Consolidated financial results for the quarter ended 30th September 2026. The trading window for dealing in shares will remain closed till 6th November 2026.

Siyaram Silk Mills Ltd reported Q2 FY27 results with revenue up 15.1% y-o-y to ₹827 crores, EBITDA of ₹131 crores, and PAT of ₹75 crores. The company declared a first interim dividend of ₹4 per equity share.

Capri Global Capital Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026, and has also approved the Limited Review Report on the same. The company has also issued an unmodified opinion in their Limited Review Report, and has provided a statement of utilization/deviation or variation in the use of proceeds from the issuance of non-convertible securities.

Syngene International Ltd reported a 13% sequential revenue growth in Q2 FY27, with operating EBITDA margin improving by 6 percentage points. The company also announced a manufacturing agreement for its Bayview biologics facility in the U.S. and strengthened its integrated drug discovery offering.